HD Insights: Volume 10

HD Insights: Volume 10

HD Insights Volume 10 (PDF)

February 23rd, 2015 Heather Hare

Editor’s Letter

January 1st, 2015 rtullio Welcome to the 10th edition of HD Insights, timed for the beginning of CHDI’s 10th Annual HD Therapeutics Conference. We are pleased to continue our mission to promote, disseminate and facilitate research in Huntington disease. We are grateful to the Huntington Study Group (HSG), our sponsors, and our more than 2600 subscribers for their continuing
+ Read More

Research Round-Up

January 1st, 2015 rtullio By: Lise Munsie, PhD In the proteome… A number of studies suggest a relationship between huntingtin (HTT) and tau protein pathology which has yet to be elucidated. Tau is found predominantly in neurons. In tauopathies such as Alzheimer disease, tau is cleaved and then aggregates. A study by Gratuze and colleagues looks at the phosphorylation
+ Read More

First-HD Results Released

January 1st, 2015 rtullio Auspex announces promising results from First-HD trial of deuterated tetrabenazine (SD-809) By: Meredith A. Achey, BM On December 16, 2014, Auspex Pharmaceuticals announced positive top-line results for the “First Time Use of SD-809 in Huntington Disease” (First-HD) registration trial of SD-809, a deuterated formulation of tetrabenazine (see HD Insights, Vol. 7). The company also released
+ Read More

Meet the Investigator

January 1st, 2015 rtullio VITAL SIGNS NAME: Francesca Cicchetti, PhD POSITION: Professor and Researcher, Neuroscience Department, Centre de Recherche du CHU de Québec, Faculty of Medicine, Laval University EDUCATION: BS, McGill University, Montréal, QC; MS and PhD in Neuroscience, Université de Laval, Québec, QC; post-doctoral work with Ole Isacson, MD, Harvard University, Cambridge, MA HOBBIES: Travel; tango and salsa
+ Read More

Highlights of HSG 2014

January 1st, 2015 rtullio By: Meredith A. Achey, BM HSG 2014 highlighted “Ideas for the future” of the HSG, exploring education, innovation, and discovery in HD research. The meeting honored outgoing leaders Dr. Ira Shoulson and Dr. Steven Hersch, and welcomed new Chair Dr. Ray Dorsey and Co-chair Dr. Blair Leavitt. Educational programming catered to both clinicians and researchers.
+ Read More

Meet the Compound: Laquinimod

January 1st, 2015 rtullio By: Ryan E. Korn, BA Manufacturer: TEVA Pharmaceutical Industries Ltd. and Active Biotech Molecular Formula: C19H17ClN2O3 Molecular Weight: 357 g/mol Mechanism of Action: Laquinimod exhibits both anti-inflammatory and neuroprotective effects. Potential mechanisms of action include its inhibition of cuprizone-induced demyelination; microglial activation; axonal transections; reactive gliosis; oligodendroglial apoptosis; as well as decreasing proinflammatory factors.1, 2
+ Read More